Home > Dermatology > EADV 2021 > Late-Breaking News > Superior EASI scores after switch from dupilumab to upadacitinib

Superior EASI scores after switch from dupilumab to upadacitinib

Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, USA
Conference
EADV 2021
Trial
Heads Up
Adults with moderate-to-severe atopic dermatitis (AD) demonstrated relevant improvements after switching from dupilumab to upadacitinib in an open-label, extension trial of the Heads Up trial. No new safety signals have been reported in the extension trial. “Upadacitinib is an oral, once-daily Janus kinase (JAK) inhibitor with greater potency for inhibiting JAK1 compared with JAK2, JAK3, and tyrosine kinase (TYK)2. It is approved by the European Commission for the treatment of adults and adolescents with moderate-to-severe AD and is under review by the FDA for this indication,” said Prof. Andrew Blauvelt (Oregon Medical Research Center, OR, USA) [1]. Following the Heads Up trial (NCT03738397), an open-label extension (OLE) study (NCT04195698) evaluated the long-term safety ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on